These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28315327)

  • 21. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.
    Lo SC; Li X; Henzl MT; Beamer LJ; Hannink M
    EMBO J; 2006 Aug; 25(15):3605-17. PubMed ID: 16888629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.
    Padmanabhan B; Tong KI; Ohta T; Nakamura Y; Scharlock M; Ohtsuji M; Kang MI; Kobayashi A; Yokoyama S; Yamamoto M
    Mol Cell; 2006 Mar; 21(5):689-700. PubMed ID: 16507366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of Keap1-phosphorylated p62 and Keap1-Nrf2 protein-protein interaction inhibitors and their inhibitory activity.
    Yasuda D; Nakajima M; Yuasa A; Obata R; Takahashi K; Ohe T; Ichimura Y; Komatsu M; Yamamoto M; Imamura R; Kojima H; Okabe T; Nagano T; Mashino T
    Bioorg Med Chem Lett; 2016 Dec; 26(24):5956-5959. PubMed ID: 27839920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational design of an epitope-specific Keap1 binding antibody using hotspot residues grafting and CDR loop swapping.
    Liu X; Taylor RD; Griffin L; Coker SF; Adams R; Ceska T; Shi J; Lawson AD; Baker T
    Sci Rep; 2017 Jan; 7():41306. PubMed ID: 28128368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
    Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
    Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
    Pallesen JS; Narayanan D; Tran KT; Solbak SMØ; Marseglia G; Sørensen LME; Høj LJ; Munafò F; Carmona RMC; Garcia AD; Desu HL; Brambilla R; Johansen TN; Popowicz GM; Sattler M; Gajhede M; Bach A
    J Med Chem; 2021 Apr; 64(8):4623-4661. PubMed ID: 33818106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
    Tran KT; Pallesen JS; Solbak SMØ; Narayanan D; Baig A; Zang J; Aguayo-Orozco A; Carmona RMC; Garcia AD; Bach A
    J Med Chem; 2019 Sep; 62(17):8028-8052. PubMed ID: 31411465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response.
    Tong KI; Padmanabhan B; Kobayashi A; Shang C; Hirotsu Y; Yokoyama S; Yamamoto M
    Mol Cell Biol; 2007 Nov; 27(21):7511-21. PubMed ID: 17785452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex.
    Bello M; Morales-González JA
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
    Pallesen JS; Tran KT; Bach A
    J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1.
    Fukutomi T; Takagi K; Mizushima T; Ohuchi N; Yamamoto M
    Mol Cell Biol; 2014 Mar; 34(5):832-46. PubMed ID: 24366543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
    Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
    Khan H; Killoran RC; Brickenden A; Fan J; Yang D; Choy WY
    Biochem J; 2015 Apr; 467(1):141-51. PubMed ID: 25582950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques.
    Londhe AM; Gadhe CG; Lim SM; Pae AN
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31726716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction.
    Abed DA; Lee S; Hu L
    Bioorg Med Chem; 2020 Mar; 28(6):115343. PubMed ID: 32046917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.
    Richardson BG; Jain AD; Potteti HR; Lazzara PR; David BP; Tamatam CR; Choma E; Skowron K; Dye K; Siddiqui Z; Wang YT; Krunic A; Reddy SP; Moore TW
    J Med Chem; 2018 Sep; 61(17):8029-8047. PubMed ID: 30122040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism.
    Horie Y; Suzuki T; Inoue J; Iso T; Wells G; Moore TW; Mizushima T; Dinkova-Kostova AT; Kasai T; Kamei T; Koshiba S; Yamamoto M
    Commun Biol; 2021 May; 4(1):576. PubMed ID: 33990683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction: a review.
    Zhuang C; Miao Z; Sheng C; Zhang W
    Curr Med Chem; 2014; 21(16):1861-70. PubMed ID: 24533814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display.
    Guntas G; Lewis SM; Mulvaney KM; Cloer EW; Tripathy A; Lane TR; Major MB; Kuhlman B
    Protein Eng Des Sel; 2016 Jan; 29(1):1-9. PubMed ID: 26489878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.